Antibacterial nucleoside natural products inhibiting phospho-MurNAc-pentapeptide translocase; Chemistry and structure-activity relationship

Current Medicinal Chemistry

Volumn 22, Issue 34, 2015, Pages 3951-3979

  Ichikawa, S ^a,b   Yamaguchi, M ^b   Matsuda, A ^a,b  

^a Center for Research and Education on Drug Discovery   (United States)

^b HOKKAIDO UNIVERSITY   (Japan)

Author keywords

Antibacterial; Drug resistance; MraY; Natural products; Nucleoside antibiotics; Total synthesis

Indexed keywords

ANTIBIOTIC AGENT; ANTIINFECTIVE AGENT; CAPURAMYCIN; MUREIDOMYCIN B; MUREIDOMYCIN C; MUREIDOMYCIN D; NUCLEOSIDE; NUCLEOSIDE DERIVATIVE; PACIDAMYCIN D; PEPTIDOGLYCAN; POLYPEPTIDE; UNCLASSIFIED DRUG; URIDINE DERIVATIVE; VANCOMYCIN; BACTERIAL PROTEIN; BIOLOGICAL PRODUCT; MRAY PROTEIN, BACTERIA; TRANSFERASE;

ARTICLE; BIOLOGICAL ACTIVITY; CRYSTAL STRUCTURE; DRUG ISOLATION; DRUG SYNTHESIS; MEMBRANE STRUCTURE; NONHUMAN; ANTAGONISTS AND INHIBITORS; BACTERIUM; CHEMISTRY; DRUG EFFECTS; METABOLISM; STRUCTURE ACTIVITY RELATION; SYNTHESIS;

ANTI-BACTERIAL AGENTS; BACTERIA; BACTERIAL PROTEINS; BIOLOGICAL PRODUCTS; NUCLEOSIDES; STRUCTURE-ACTIVITY RELATIONSHIP; TRANSFERASES;

EID: 84957534889     PISSN: 09298673     EISSN: 1875533X     Source Type: Journal    
DOI: 10.2174/0929867322666150818103502     Document Type: Article

References (151)

1. Rachakonda, S.; Cartee, L. Challenges in antimicrobial drug discovery and the potential of nucleoside antibiotics. Curr. Med. Chem., 2004, 11, 775-793.
2. Barbachyn, M. R.; Ford, C. W. Oxazolidinone structureactivity relationships leading to linezolid. Angew. Chem. Int. Ed., 2003, 42, 2010-2023.
3. Raja, A.; LaBonte, J.; Lebbos, J.; Kirkpatrick, P. Daptomycin. Nat. Rev. Drug Discov., 2003, 2, 943-944.
4. Alder, J. D. Daptomycin: A new drug class for the treatment of Gram-positive infections. Drugs Today, 2005, 41, 81-90.
5. Scott, L. Fidaxomicin: A review of its use in patients with Clostridium difficile infection. Drugs, 2013, 15, 1733-1747.
6. Fox, G. J.; Menzies, D. A review of the evidence for using bedaquiline (TMC207) to treat multi-drug resistant tuberculosis. Infect. Dis. Ther., 2013, 2, 123-144.
7. a) Newman, D. J.; Cragg, G. M. Natural products as sources of new drugs over the 30 years from 1981 to 2010. J. Nat. Prod., 2012, 75, 311-335.
8. b) Newman, D. J.; Cragg, G. M. Natural products as sources of new drugs over the last 25 years. J. Nat. Prod., 2007, 70, 461-477.
9. c) O'Shea, R.; Moser, H. E. Physicochemical properties of antibacterial compounds: Implications for drug discovery. J. Med. Chem., 2008, 51, 2871-2878.
10. von Nussbaum, F.; Brands, M.; Hinzen, B.; Weigand, S;. Habich, D. Antibacterial natural products in medicinal chemistry-exodus or revival? Angew. Chem. Int. Ed., 2006, 45, 5072-5129.
11. O'Shea, R.; Moser, H. E. Physicochemical properties of antibacterial compounds: Implications for drug discovery. J. Med. Chem., 2008, 51, 2871-2878.
12. Suhadolnik, R. J. Nucleosides as Biological Probes. Wiley Interscience, New York, 1979.
13. Goodchild, J. The biochemistry of nucleoside antibiotics. Top. Antibiot. Chem., 1982, 6, 99-227.
14. Buchanan, J. G.; Wightman, R. H. The chemistry of nucleoside antibiotics. Top. Antibiot. Chem., 1982, 6, 229-339.
15. Isono, K. Nucleoside antibiotics: Structure, biological activity, and biosynthesis. J. Antibiot., 1988, 41, 1711-1739.
16. Isono, K. Current progress on nucleoside antibiotics. Pharmacol. Ther., 1991, 52, 296-286.
17. Ichikawa, S.; Matsuda, A. Nucleoside natural products and related analogs. Expert Opin. Ther. Pat., 2007, 17, 487-498.
18. Bouhss, A.; Trunkfield, A. E.; Bugg, T. D.; Mengin-Lecreulx, D. The biosynthesis of peptidoglycan lipid-linked intermediates. FEMS Microbiol. Rev., 2008, 32, 208-233.
19. a) Winn, M.; Goss, R. J. M.; Kimura, K.; Bugg, T. D. H. Antimicrobial nucleoside antibiotics targeting cell wall assembly: Recent advances in structure-function studies and nucleoside biosynthesis. Nat. Prod. Rep., 2010, 27, 279-304.
20. b) Bugg, T. D. H.; Lloyd, A. J.; Roper, D. I. Phospho-MurNAc-pentapeptide translocase (MraY) as a target for antibacterial agents and antibacterial proteins. Infect. Dis. Drug Targets, 2006, 6, 85-106.
21. c) Kimura, K.; Bugg, T. D. H. Phospho-MurNAc-pentapeptide translocase (MraY) as a target for antibacterial agents and antibacterial proteins. Nat. Prod. Rep., 2003, 20, 252-273.
22. Knapp, S. Synthesis of complex nucleoside antibiotics. Chem. Rev., 1995, 95, 1859-1876.
23. Tamura, G.; Sasaki, T.; Matsuhashi, M.; Takatsuki, A.; Yamasaki, M. Tunicamycin inhibits the formation of lipid intermediate in cell-free peptidoglycan synthesis of bacteria. Agric. Biol. Chem., 1976, 40, 447-449.
24. Tamura, G. Tunicamycin; Japan Scientific Press: Tokyo, 1982.
25. Struve, W. G.; Sinha, R. K.; Neuhaus, F. C. On the initial stage in peptidoglycan synthesis. Phospho-Nacetylmuramyl-peptapeptide translocase (uridine monophosphste). Biochemistry, 1966, 5, 82-93.
26. Al-Dabbagh, B.; Henry, X.; El Ghachi, M.; Auger, G.; Blanot, D.; Parquet, C.; Mengin-Lecreulx, D.; Bouhss, A. Active site mapping of MraY, a member of the polyprenylphosphate N-acetylhexosamine 1-Phosphate transferase superfamily, catalyzing the first membrane step of peptidoglycan biosynthesis. Biochemistry, 2008, 47, 8919-8928.
27. Bouhss, A.; Mengin-Lecreulx, D.; Le Beller, D.; Van Heijenoort, J. Topological analysis of the MraY protein catalyzing the first membrane step of peptidoglycan synthesis. Mol. Microbiol., 1999, 34. 576-585.
28. Amer, A. O; Valvano, M. A. Conserved amino acid residues found in a predicted cytosolic domain of the lipopolysaccharide biosynthetic protein WecA are implicated in the recognition of UDP-N-acetylglucosamine. Microbiology, 2001, 147, 3015-3025.
29. Amer, A. O.; Valvano, M. A. Conserved aspartic acids are essential for the enzymic activity of the WecA protein initiating the biosynthesis of O-specific lipopolysaccharide and enterobacterial common antigen in Escherichia coli. Microbiology, 2002, 148, 571-582.
30. Chung, B. C.; Zhao, J.; Kwon, D.-Y.; Guan, Z.; Hong, J.; Zhou, P.; Lee, S.-Y. Crystal structure of MraY, an essential membrane enzyme for bacterial cell wall synthesis. Science, 2013, 341, 1012-1016.
31. Isono, K.; Uramoto, M.; Kusakabe, H.; Kimura, K.; Izaki, K.; Nelson, C. C.; McCloskey, J. A. Liposidomycins: Novel nucleoside antibiotics which inhibit bacterial peptidoglycan synthesis. J. Antibiot., 1985, 38, 1617-1621.
32. Ubukata, M.; Kimura, K.; Isono, K.; Nelson, C. C.; Gregson, J. M.; McCloskey J. A. Structure elucidation of liposidomycins, a class of complex lipid nucleoside antibiotics. J. Org. Chem., 1992, 57, 6392-6403.
33. a) Ubukata, M.; Isono, K. The structure of liposidomycin B, an inhibitor of bacterial peptidoglycan synthesis. J. Am. Chem. Soc. 1988, 110, 4416-4417.
34. b) Muroi, M.; Kimura, K.; Osada, H.; Inukai, M.; Takatsuki, A. Liposidomycin B inhibits in vitro formation of polyprenyl (pyro)phosphate Nacetylglucosamine, an intermediate in glycoconjugate biosynthesis. J. Antibiot., 1997, 50, 103-104.
35. Kimura, K.; Miyata, N.; Kawanishi, G.; Kamio, Y.; Izaki, K.; Isono, K. Liposidomycin C inhibits phospho-Nacetylmuramyl-pentapeptide transferase in peptidoglycan synthesis of Escherichia coli Y-10. Agric. Biol. Chem., 1989, 53, 1811-1815.
36. a) Kimura, K.; Kagami, S.; Ikeda, Y.; Takahashi, H.; Yoshihama, M.; Kusakabe, H.; Osada, H.; Isono, K. New types of liposidomycins that inhibit bacterial peptidoglycan synthesis and are produced by Streptomyces. I. Producing organism and medium components. J. Antibiot. 1998, 51, 640-646.
37. b) Kimura, K.; Ikeda, Y.; Kagami, S.; Yoshihama, M.; Ubukata, M.; Esumi, Y.; Osada, H.; Isono, K. New types of liposidomycins that inhibit bacterial peptidoglycan synthesis and are produced by Streptomyces. II. Isolation and structure elucidation. J. Antibiot. 1998, 51, 647-654.
38. c) Kimura, K.; Ikeda, Y.; Kagami, S.; Yoshihama, M.; Suzuki, K.; Osada, H.; Isono, K.; Selective inhibition of the bacterial peptidoglycan biosynthesis by the new types of liposidomycins. J. Antibiot., 1998, 51, 1099-1104.
39. a) Igarashi, M.; Nakagawa, N.; Doi, N.; Hattori, S.; Naganawa, H.; Hamada, M. Caprazamycin B, a novel antituberculosis antibiotic, from Streptomyces sp. J. Antibiot., 2003, 56, 580-583.
40. b) Igarashi, M.; Takahashi, Y.; Shitara, T.; Nakamura, H.; Naganawa, Miyake T, Akamatsu Y: Caprazamycins, novel lipo-nucleoside antibiotics, from Streptomyces sp. J. Antibiot., 2005, 58, 327-337.
41. Muramatsu, Y.; Yoko, F.; Azusa, A.; Masaaki K, Toshio T, Shunichi M. 2004046368. Sankyo Co., Ltd; Patent WO. 2004.
42. Sankyo Co. Ltd.: JP247725, 2005.
43. Fujita, Y.; Kizuka, M.; Funabashi, M.; Ogawa, Y.; Ishikawa, T.; Nonaka, K.; Takatsu, T. A-90289 A and B, new inhibitors of bacterial translocase I, produced by Streptomyces sp. SANK 60405. J. Antibiot., 2011, 64, 495-501.
44. Spada, M. R.; Ubukata, M.; Isono, K. Stereospecific synthesis of a ribosyl-diazepanone derivative; a synthetic approach for elucidation of the stereochemistry of a lipid nucleoside antibiotic liposidomycin B. Heterocycles, 1992, 34, 1147-1167.
45. a) Knapp, S.; Morriello, G. J.; Doss, G. A. Synthesis of the liposidomycin diazepanone nucleoside. Org. Lett. 2002, 4, 603-606.
46. b) Knapp, S.; Morriello, G. J.; Nandan, S. R.; Emge, T. J.; Doss, G. A.; Mosley, R. T.; Chen, L. Assignment of the liposidomycin diazepanone stereochemistry. J. Org. Chem., 2001, 66, 5822-5831.
47. c) Knapp, S.; Nandan, S.; Resnick, L. Synthesis of the liposidomycin diazepanone. Tetrahedron Lett., 1992, 33, 5485-5486.
48. d) Knapp, S.; Morriello, G. J.; Doss, G. A. A Stevens rearrangement thwarts glycosylation with liposidomycin diazepanone ribofuranosyl donors. Tetrahedron Lett., 2002, 43, 5797-5800.
49. Nakajima, N.; Isobe, T.; Irisa, S.; Ubukata, M. Toward the assignment of liposidomycin stereochemistry: Synthesis of 1,4-diazepan-3-one analogues by reductive amination approach. Heterocycles, 2003, 59, 107-113.
50. a) Gravier-Pelletier, C.; Milla, M.; Le Merrer, Y.; Depezay, J. Liposidomycins: Synthetic studies towards the ribosyldiazepanone moiety. Eur. J. Org. Chem. 2001, 3089-3096.
51. b) Gravier-Pelletier, C.; Dumas, J.; Le Merrer, Y.; Depezay, J. C. A general way, from L-ascorbic and D-isoascorbic acid, to homochiral a-hydroxy, a,β-dihydroxy and a,β-epoxyaldehydes, useful building blocks for the synthesis of linear oxygenated fatty acids metabolites. J. Carbohydr. Chem. 1992, 11, 969-998.
52. c) Le Merrer, Y.; Gravier-Pelletier, C.; Gerrouache, M.; Depezay, J. C. Accesss to enatiopure ribosyl-diazepanone core of liposidomycins. Tetrahedron Lett., 1998, 39, 385-388.
53. d) Gravier-Pelletier, C.; Ginisty, M.; Le Merrer, Y. A versatile scaffold for a library of liposidomycins analogues: A crucial and potent glycosylation step. Tetrahedron Asymmetry 2004, 15, 189-193.
54. e) Ginisty, M.; Gravier-Pelletier, C.; Le Merrer, Y. Chemical investigations in the synthesis of O-serinyl aminoribosides. Tetrahedron Asymmetry, 2006, 17, 142-150.
55. a) Drouillat, B.; Poupardin, O.; Bourdreux, Y.; Greck, C. Diastereoselective syntheses of a-amino-β-hydroxyesters precursors of ribosyl-diazepanone core of the liposidomycins. Tetrahedron Lett., 2003, 44, 2781-2783.
56. b) Bourdreux, Y.; Drouillat, B.; Greck, C. Convergent synthetic studies towards the ribosyl-diazepanone core of the liposidomycins. Lett. Org. Chem., 2006, 3, 368-370.
57. c) Drouillat, B.; Bourdreux, Y.; Perdon, D.; Greck, C. Synthetic route towards (5R,2′S,5′S,6′S)-ribosyl-diazepanone, an analogue core of the liposidomycins. Tetrahedron Asymmetry, 2007, 18, 1955-1963.
58. a) Kim, K. S.; Ahn, Y. H. Synthesis of the diazepanonenucleoside portion of liposidomycins by aldol reaction of the enolate of diazepanone with a nucleoside 5′-aldehyde. Tetrahedron: Asymmetry, 1998, 9, 3601-3605.
59. b) Kim, K. S.; Cho, I. H.; Ahn, Y. H.; Park, J. I. Synthesis of the 1,4-diazepanone-2-one moiety of liposidomycins. J. Chem. Soc. Perkin Trans. 1 1995, 1783-1785.
60. c) Kim, K. S.; Cheong, C. S.; Hahn, J. S.; Park, J. I. B Synthetic study on lipid part of liposidomycins. Bull. Korean Chem. Soc., 1997, 18, 465-467.
61. (a) Sarbia, F.; Martin-Ortiz, L.; Lopez-Herrera, F. J. A convergent synthetic approach to the nucleoside-type liposidomycin antibiotics. Org. Lett. 2003, 21, 3927-3930.
62. (b) Sarabia, F.; Vivar-Garcia, C.; Garcia-Ruiz, C.; Martin-Ortiz, L.; Romero-Carrasco, A. Exploring the chemistry of epoxy amides for the synthesis of the 2′′-epi-diazepanone core of liposidomycins and caprazamycins. J. Org. Chem., 2012, 77, 1328-1339.
63. Spork, A. P.; Koppermann, S.; Dittrich, B.; Herbst-Irmer, R.; Ducho, C. Efficient synthesis of the core structure of muraymycin and caprazamycin nucleoside antibiotics based on a stereochemically revised ylide reaction. Tetrahedron Asymmetry, 2010, 21, 763-766.
64. Jung, K.; Muller, M.; Schmidt, R. R. Intramolecular Oglycoside bond formation. Chem. Rev., 2000, 100, 4423-4442.
65. a) Hirano, S.; Ichikawa, S.; Matsuda, A. Development of a highly β-selective ribosylation reaction without using neighboring group participation: Total synthesis of (+)-caprazol, a core structure of caprazamycins. J. Org. Chem., 2007, 72, 9936-9946.
66. b) Hirano, S.; Ichikawa, S.; Matsuda, A. Total synthesis of caprazol, a core structure of the caprazamycin antituberculosis antibiotics. Angew. Chem. Int. Ed., 2005, 44, 1854-1856.
67. Ichikawa, S.; Hayashi, R.; Hirano, S.; Matsuda, A. Highly β-selective C-allylation of a ribofuranoside controlling steric hindrance in the transition state. Org. Lett., 2008, 10, 5107-5110.
68. Gopinath, P.; Wang, L.; Abe, H.; Ravi, G.; Masuda, T.; Watanabe, T.; Shibasaki, M. Catalytic asymmetric total synthesis of (+)-caprazol. Org. Lett., 2014, 16, 3364-3367.
69. Nakamura, H.; Tsukamoto, C.; Yasui, M.; Yokouchi, S.; Igarashi, M.; Takemoto, Y. Total synthesis of (-)-caprazamycin A. Angew. Chem. Int. Ed., 2015, 54, 3136-3139.
70. Abe, H.; Gopoinath, P.; Ravi, G.; Wang, L.; Watanabe, T.; Shibasaki, M. Synthesis of caprazamycin B. Tetrahedron Lett., 2015, 56, 3782-3785.
71. a) Dini, C.; Collette, P.; Drochon, N.; Guillot, J. C.; Lemoine, G.; Mauvais, P.; Aszodi, J. Synthesis of nucleoside moiety of liposidomycins: Elucidation of the pharmacophore of this family of MraY inhibitor. Bioorg. Med. Chem. Lett., 2000, 10, 1839-1843.
72. b) Dini, C.; Drochon, N.; Guillot, J. C.; Mauvais, P.; Walter, P.; Aszodi, J. Synthesis of analogues of the O-β-D-ribofuranosyl nucleoside moiety of liposidomycins. Part 2: Role of the hydroxyl groups upon the inhibition of MraY. Bioorg. Med. Chem. Lett., 2001, 11, 533-536.
73. c) Dini, C.; Drochon, N.; Feteanu, S.; Guillot, J. C.; Peixoto, C.; Aszodi, J. Synthesis of analogues of the O-β-D-ribofuranosyl nucleoside moiety of liposidomycins. Part 1: Contribution of the amino group and the uracil moiety upon the inhibition of MraY. Bioorg. Med. Chem. Lett., 2001, 11, 529-531.
74. Dini, C.; Didier-Laurent, S.; Drochon, N.; Fereanu, S.; Guillot, J. C.; Monti, F.; Uridat, E.; Zhang, J.; Aszodi, J. Synthesis of sub-micromolor inhibitors of MraY by exploring the region originally occupied by the diazepanone ring in the liposidomycin structure. Bioorg. Med. Chem. Lett., 2002, 12, 1209-1213.
75. Hirano, S.; Ichikawa, S.; Matsuda, A. Synthesis of caprazamycin analogs and their structure-activity relationship for antibacterial activity. J. Org. Chem., 2008, 73, 569-577.
76. Ichikawa, S.; Yamaguchi, M.; Hsuan, L. S.; Kato, Y.; Matsuda, A. Carbacaprazamycins: chemically stable analogues of the caprazamycin nucleoside antibiotics. ACS Infect. Dis., 2015, 1, 151-156.
77. a) Hirano, S.; Ichikawa, S.; Matsuda, A. Structure-activity relationship of truncated analogs of caprazamycins as potential anti-tuberculosis agents. Bioorg. Med. Chem., 2008, 16, 5123-5133.
78. b) Hirano, S.; Ichikawa, S.; Matsuda, A. Design and synthesis of diketopiperazine and acyclic analogs related to the caprazamycins and liposidomycins as potential antibacterial agents. Bioorg. Med. Chem., 2008, 16, 428-436.
79. a) Takahashi, Y.; Igarashi, M.; Miyake, T.; Soutome, H.; Ishikawa, K.; Komatsuki, Y.; Koyama, Y.; Nakagawa, N.; Hattori, S.; Inoue, K.; Doi, N.; Akamatsu, Y. Novel semisynthetic antibiotics from caprazamycins A-G: Caprazene derivatives and their antibacterial activity. J. Antibiot., 2013, 66, 171-178.
80. Ishizaki, Y.; Hayashi, C.; Inoue, K.; Igarashi, M.; Takahashi, Y.; Pujari, V.; Crick, D. C.; Brennan, P. J.; Nomoto, A. Inhibition of the first step in synthesis of the mycobacterial cell wall core, catalyzed by the GlcNAc-1-phosphate transferase WecA, by the novel caprazamycin derivative CPZEN-45. J. Biol. Chem., 2013, 228, 30309-30319.
81. Branco, F. S. C.; Pinto, A. C.; Boechat, N. An update on the chemistry and medicinal chemistry of novel antimycobacterial compounds. Curr. Top. Med. Chem., 2013, 13, 2808-2849.
82. Hanif, S. N. M.; Hickey, A. J.; Garcia-Contreras, L. Liquid chromatographic determination of CPZEN-45, a novel antitubercular drug, in biological samples. J. Pharm. Biomed. Anal., 2014, 88, 370-376.
83. Engohang-Ndong, J. Antimycobacterial drugs currently in Phase II clinical trials and preclinical phase for tuberculosis treatment. Expert. Opin. Investig. Drugs, 2012, 21, 1789-1800.
84. a) Fer, M. J.; Bouhss, A.; Patrao, M.; Le Corre, L.; Pietrancosta, N.; Amoroso, A.; Joris, B.; Mengin-Lecreulx, D.; Calvet-Vitale, S.; Gravier-Pelletier, C. 5′-Methylenetriazole-substituted-aminoribosyl uridines as MraY inhibitors: Synthesis, biological evaluation and molecular modeling. Org. Biomol. Chem., 2015, 13, 7193-7222.
85. b) Fer, M. J.; Olatunji, S.; Bouhss, A.; Calvet-Vitale, S.; Gravier-Pelletier, C. Toward analogues of mray natural inhibitors: Synthesis of 5′-triazole-substituted-aminoribosyl uridines through a Cu-catalyzed azide-alkyne cycloaddition. J. Org. Chem., 2013, 78, 10088-10105.
86. a) Monasson, O.; Ginisty, M.; Bertho, G.; Gravier-Pelletier, C.; Le Merrer, Y. Efficient synthesis of polyfunctionalised enantiopure diazepanone scaffolds. Tetrahedron Lett., 2007, 48, 8149-8152.
87. b) Mravljak, J.; Monasson, O.; Al-Dabbagh, B.; Crouvoisier, M.; Bouhss, A.; Gravier-Pelletier, C.; Le Merrer, Y. Synthesis and biological evaluation of a diazepanone-based library of liposidomycins analogs as MraY inhibitors. Eur. J. Med. Chem., 2011, 46, 1582-1592.
88. Mcdonald, L. A.; Barbieri, L. R.; Carter, G. T.; Lenoy, E.; Lotvin, J.; Petersen, P. J.; Siegel, M. M.; Singh, G.; Williamson, R. T. Structure of the muraymycins, novel peptidoglycan biosynthesis inhibitors. J. Am. Chem. Soc., 2002, 124, 10260-10261.
89. Tanino, T.; Ichikawa, S.; Shiro, M.; Matsuda, A. Total synthesis of (-)-muraymycin D2 and its epimer. J. Org. Chem., 2010, 75, 1366-1377.
90. Tanino, T.; Ichikawa, S.; Matsuda, A. Synthesis of L-epicapreomycidine derivatives via C-H amination. Org. Lett., 2011, 13, 4028-4031.
91. a) Spork, A. P.; Koppermann, S.; Ducho, C. Improved convergent synthesis of 5′-epi-analogues of muraymycin nucleoside antibiotics, Synlett, 2009, 2503-2507.
92. b) Spork, A. P.; Ducho, C. Novel 5′-deoxy nucleosyl amino acid scaffolds for the synthesis of muraymycin analogues. Org. Biomol. Chem., 2010, 8, 2323-2326.
93. c) Spork, A. P.; Wiegmann, D.; Granitzka, M.; Stalke, D.; Ducho, C. Stereoselective synthesis of uridine-derived nucleosyl amino acids. J. Org. Chem. 2011, 76, 10083-10098.
94. d) Spork, A. P.; Ducho, C. Stereocontrolled synthesis of 5′-and 6′-epimeric analogues of muraymycin nucleoside antibiotics. Syn. Lett., 2013, 343-346.
95. Aleiwi, B. A.; Schmeider, C. M.; Kurosu, M. Synthesis of ureidomuraymycidine derivatives for structure-activity relationship studies of muraymydins. J. Org. Chem., 2012, 77, 3859-3867.
96. Lin, Y. I.; Li, Z.; Francisco, G. D.; McDonald, L. A.; Davis, R. A.; Singh, G.; Yang, Y.; Mansour, T. S. Muraymycins, novel peptidoglycan biosynthesis inhibitors: Semisynthesis and SAR of their derivatives. Bioorg. Med. Chem. Lett., 2002, 12, 2341-2344.
97. Yamashita, A.; Norton, E.; Peterson, P. J.; Rasmussen, B. A.; Singh, G.; Yang, Y.; Mansour, T. S.; Ho, D. M. Muraymycins, novel peptidoglycan biosynthesis inhibitors: Synthesis and SAR of their analogues. Bioorg. Med. Chem. Lett., 2003, 13, 3345-3350.
98. Spork, A. P.; Bueschleb, M.; Ries, O.; Wiegmann, D.; Boettcher, S.; Mihalyi, A.; Bugg, T. D. H.; Ducho, C. Lead structure for new antibacterials: Stereocontrolled synthesis of a bioactive muraymycin analogue. Chem. Eur. J., 2014, 20, 15292-15297.
99. Tanino, T.; Ichikawa, S.; Al-Dabbagh, B.; Bouhss, A.; Matsuda, A. Synthesis and biological evaluation of muraymycin analogues as potential anti-drug-resistant bacterial. ACS Med. Chem. Lett., 2010, 1, 258-262.
100. Tanino, T.; Al-Dabbagh, B.; Mengin-Lecreulx, D.; Bouhss, A.; Oyama, H.; Ichikawa, S.; Matsuda, A. Mechanistic analysis of muraymycin analogues: A guide to the design of MraY inhibitors. J. Med. Chem., 2011, 54, 8421-8439.
101. a) Yamaguchi, H.; Sato, S.; Yoshida, S.; Takada, K.; Itoh, M.; Seto, H.; Otake, N. Capuramycin, A new nucleoside antibiotic. Taxonomy, fermentation, isolation and characterization. J. Antibiot., 1986, 39, 1047-1053.
102. b) Seto, H.; Otake, N.; Sato, S.; Hamaguchi, H.; Takada, K.; Itoh, M.; Lu, H. S. M.; Clardy, J. The structure of a new nucleoside antibiotic, capuramycin. Tetrahedron Lett., 1988, 29, 2343-2346.
103. c) Murakami, R.; Fujita, Y.; Kizuka, M.; Kagawa, T.; Muramatsu, Y.; Miyakoshi, S.; Takatsu, T.; Inukai, M. A-102395, a novel inhibitor of bacterial translocase I, produced by Amycolatopsis sp. SANK 60206. J. Antibiot., 2007, 60, 690-695.
104. a) Muramatsu, Y.; Muramatsu, A.; Ohnuki, T.; Ishii, M. M.; Kizuka, M.; Enokita, R.; Tsutsumi, S.; Arai, M.; Ogawa, Y.; Suzuki, T.; Takatsu, T.; Inukai, M. Studies on novel bacterial translocase I inhibitors, A-500359S. Taxonomy, fermentation, isolation, physico-chemical properties and structure elucidation of A-500359A, C, D and G. J. Antibiot., 2003, 56, 243-252.
105. b) Muramatsu, Y.; Arai, M.; Sakaida, Y.; Takamatsu, Y.; Miyakoshi, S.; Inukai, M. Studies on novel bacterial translocase I inhibitors, A-500359S. J. Antibiot., 2006, 59, 601-606.
106. Knapp, S.; Nanda, S. R. Synthesis of capuramycin. J. Org. Chem., 1994, 59, 281-283.
107. a) Kurosu, M.; Li, K.; Crick, D. C. Concise synthesis of capuramycin. Org. Lett., 2009, 11, 2393-2396.
108. b) Wang, Y.; Siricilla, S.; Aleiwi, B. A.; Kurosu, M. Improved synthesis of capuramycin and its analogues. Chem. Eur. J., 2013, 19, 13847-13858.
109. a) Hotoda, H.; Furukawa, M.; Daigo, M.; Murayama, K.; Kaneko, M.; Muramatsu. Y.; Ishi, M. M.; Miyakoshi, S.; Takatsu, T.; Inukai, M.; Kakuta, M.; Abe, T.; Harasaki, T.; Fukuoka, T.; Utsui, Y.; Ohya, S. Synthesis and antimycobacterial activity of capuramycin analogues. Part 1: Substitution of the azepan-2-one moiety of capuramycin. Bioorg. Med. Chem. Lett., 2003, 13, 2829-2832.
110. b) Hotoda, H.; Daigo, M.; Furukawa, M.; Murayama, K.; Hasegawa, C. A.; Kaneko, M.; Muramatsu, Y.; Ishi, M. M.; Miyakoshi, S.; Takatsu, T.; Inukai, M.; Kakuta, M.; Abe, T.; Fukuoka, T.; Utsui, Y.; Ohya, S. Synthesis and antimycobacterial activity of capuramycin analogues. Part 2: Acylated derivatives of capuramycin-related compounds. Bioorg. Med. Chem. Lett., 2003, 13, 2833-2836.
111. c) Koga, T.; Fukuoka, T.; Doi, N.; Harasaki, T.; Inoue, H.; Hotoda, H.; Kakuta, M.; Muramatsu, Y.; Yamamura, N.; Hoshi, M.; Hirota, T. Activity of capuramycin analogues against Mycobacterium tuberculosis, Mycobacterium avium and Mycobacterium intracellulare in vitro and in vivo. J. Antibicrob. Chemother., 2004, 54, 755-760.
112. a) Nikonenko, B.; Reddy, V. M.; Bogatcheva, E.; Protopopova, M.; Einck, L.; Nancy, C. A. Threrapeutic efficacy of SQ641-NE against Mycobacterium tuberculosis. Antimicrob. Agents Chemother., 2014, 58, 587-589.
113. b) Nikonenko, B.; Reddy, V. M.; Protopopova, M.; Bogatcheva, E.; Einck, L.; Nancy, C. A. Activity of SQ641, a capuramycin analog, in a murine model of tuberculosis. Antimicrob. Agents Chemother., 2009, 53, 3138-3139.
114. c) Bogatcheva, E.; Dubuisson, T.; Protopopova, M.; Einck, L.; Nancy, C. A.; Reddy, V. M. Chemical modification of capuramycins to enhance antibacterial activity. J. Antimicrob. Chemother., 2011, 66, 578-587.
115. d) Nikonenko, B. V.; Reddy, V. M.; Protopopova, M.; Bogatcheva, E.; Einck, L.; Nacy, C. A. Activity of SQ641, a capuramycin analogue, in a murine model of tuberculosis. Antimicrob. Agents Chemother., 2009, 53, 3138-3139.
116. e) Reddy, V. M.; Einck, L.; Nacy, C. A. In vitro antimycobacterial activities of capuramycin analogues. Antimicrob. Agents Chemother., 2008, 52, 719-721.
117. a) Siricilla, S.; Mitachi, K.; Wan, B.; Franzblau, S. G.; Kurosu, M. Discovery of a cauramycin analog that kill nonreplicating Mycobacterium tuberculosis and its synergistic effects with translocase I inhibitors. J. Antibiot., 2014, 67, 1-8.
118. b) Aleiwi, B. A.; Kurosu, M. A reliable Pd-mediated hydrogenolytic deprotection of BOM group of uridine ureido nitrogen. Tetrahedron Lett., 2012, 53, 3758-3762.
119. c) Kurosu, M.; Li, K. Highly efficient O-glycosylations with p-tolyl thioribosides and p-TolSOTf. J. Org. Chem., 2008, 73, 9767-9770.
120. a) Inukai, M.; Isono, F.; Takahashi, S.; Enokita, R.; Sakaida, Y.; Haneishi, T. Mureidomycins AD, novel peptidyl nucleoside antibiotics with speroplast forming activity. I. taxonomy, fermentation, isolation and physicochemical properties. J. Antibiot., 1989, 42, 662-666.
121. b) Isono, F.; Inukai, M. Mureidomycin A, a new inhibitor of bacterial peptidoglycan synthesis. Antimicrob. Agents Chemother. 1991, 35, 234-236.
122. c) Inukai, M.; Isono, F.; Takatsuki, A. Selective inhibition of the bacterial translocase reaction in peptidoglycan synthesis by mureidomycins. Antimicrob. Agents Chemother., 1993, 37, 980-983.
123. d) Isono, F.; Katayama, T.; Inukai, M.; Haneishi, T. Mureidomycins A-D, novel peptidylnucleoside antibiotics with spheroplast forming activity. III. biological properties. J. Antibiot., 1989, 42, 674-679.
124. e) Isono, F.; Inukai, M.; Takahashi, S.; Haneishi, T.; Kinoshita, T.; Kuwano, H. Mureidomycins A-D, novel peptidylnucleoside antibiotics with spheroplast forming activity. II. Structural elucidation. J. Antibiot., 1989, 42, 667-673.
125. f) Isono, F.; Sakaida, Y.; Takahashi, S.; Kinoshita, T.; Nakamura, T.; Inukai, M. Mureidomycins E and F, minor components of mureidomycins. J. Antibiot., 1993, 46, 1203-1207.
126. Chatterjee, S.; Nadkarni, S. R.; Vijayakumar, E. K. S.; Patel, M. V.; Ganguli, B. N.; Fehlhaber, H. W.; Vertesy, L. Napsamycins, new pseudomonas active antibiotics of the mureidomycin family from Streptomyces sp. Hily-82, 11372. J. Antibiot., 1994, 47, 595-598.
127. a) Karwowski, J. P.; Jackson, M.; Theriault, R. J.; Chen, R. H.; Barlow. G. J.; Maus, M. L. Pacidamycins, a novel series of antibiotics with antl-Pseudomonas aeruginosa activity. I. taxonomy of the producing organism and fermentation. J. Antibiot., 1989, 42, 506-511.
128. b) Chen, R. H.; Buko, A. M.; Whittern, D. N.; Mcalpin, J. Pacidamycins, a novel series of antibiotics with anti-Pseudomonas aeruginosa activity. II. isolation and structural elucidation. J. Antibiot., 1989, 42, 512-520.
129. c) Fernandes, P. B.; Swanson, R. N.; Hardy, D. J.; Hanson, C. W.; Coen, L.; Rasmussen, R. R.; Chen, R. H. Pacidamycins, a novel series of antibiotics with anti-Pseudomonas aeruginosa activity. III. microbiologic profile. J. Antibiot., 1989, 42, 521-526.
130. Fronko, R. M.; Lee, J. C.; Galazzo, J. G.; Chamberland, S.; Malouin, F.; Lee, M. D. New pacidamycins produced by Streptomyces coeruleorubidus, NRRL 18370. J. Antibiot., 2000, 53, 1405-1410.
131. a) Xie, Y.; Chen, R.; Si, S.; Sun, C.; Xu, H. A new nucleosidyl-peptide antibiotic, Sansanmycin. J. Antibiot., 2007, 60, 158-161.
132. b) Xie, Y.; Xu, H.; Si, S.; Sun, C.; Chen, R. Sansanmycins B and C, new components of sansanmycins. J. Antibiot., 2008, 61, 237-240.
133. Gentl, C. A.; Bugg, T. D. H. Role of the enamide linkage of nucleoside antibiotic mureidomycin A: Synthesis and reactivity of enamide-containing analogues. J. Chem. Soc. Perkin Trans., 1999, 1, 1279-1286.
134. a) Okamoto, K.; Sakagami, M.; Feng, F.; Togame, H.; Takemoto, H.; Ichikawa, S.; Matsuda A. Total synthesis and biological evaluation of pacidamycin D and its 3′-hydroxy analogue. J. Org. Chem., 2012, 77, 1367-1377.
135. b) Okamoto, K.; Sakagami, M.; Feng, F.; Togame, H.; Takemoto, H.; Ichikawa, S.; Matsuda A. Total synthesis of pacidamycin D by Cu(I)-catalyzed oxy enamide formation. Org. Lett., 2011, 13, 5240-5243.
136. c) Okamoto, K.; Sakagami, M.; Feng, F.; Takahashi, F.; Uotani, K.; Togame, H.; Takemoto, H.; Ichikawa, S.; Matsuda, A. Synthesis of pacidamycin analogues via an Ugi-multicomponent reaction. Bioorg. Med. Chem. Lett., 2012, 22, 4810-4815.
137. a) Gentle, C. A.; Harrison, S. A.; Inukai, M.; Bugg, T. D. H. Structure-function studies on nucleoside antibiotic mureidomycin A: Synthesis of 5′-functionalised uridine models. J. Chem. Soc. Perkin Trans.,1999, 1, 1287-1294.
138. b) Howard, N. I.; Bugg, T. D. H. Synthesis and activity of 5′-Uridinyl dipeptide analogues mimicking the amino terminal peptide chain of nucleoside antibiotic mureidomycin A. Bioorg. Med. Chem., 2003, 11, 3083-3099.
139. Boojamra, C. G.; Lemoine, R. C.; Nlais, J.; Vernier, N. G.; Stein, K. A.; Magon, A.; Chamberland, S.; Hecker, S. J.; Lee V. J. Synthetic dihydropacidamycin antibiotics: A modified spectrum of activity for the pacidamycin class. Bioorg. Med. Chem. Lett., 2003, 13, 3305-3309.
140. Lemoine, R. C.; Magon, A.; Hecker, S. Synthesis of basemodified dihydropacidamycins. Bioorg. Med. Chem. Lett., 2002, 12, 1121-1123.
141. Sun, D.; Jones, V.; Carson, E. I.; Lee, R. E. B.; Scherman, M. S.; McNeil, M. R.; Lee, R. E. Solid-phase synthesis and biological evaluation of a uridinyl branched peptide urea library. Bioorg. Med. Chem. Lett., 2007, 17, 6899-6904.
142. Bozzoli, A.; Kazmierski, W.; Kennedy, G.; Pasquarello, A.; Pecunioso, A. A solid-phase approach to analogues of the antibiotic mureidomycin. Bioorg. Med. Chem. Lett., 2000, 10, 2759-2763.
143. a) Gruschow, S.; Rackham, E. J.; Elkins, B.; Newill, P. L. A.; Hill, L. M.; Goss, R. J. M. New Pacidamycin Antibiotics Through Precursor-Directed Biosynthesis. Chem. Bio. Chem., 2009, 10, 355-360.
144. b) Deb Roy, A.; Gruschow, S.; Cairns, N.; Goss, R. J. M. New Gene express enabling synthetic diversification of natural products: Chemogenetic generation of pacidamycin analogs. J. Am. Chem., Soc., 2010, 132, 12243-12245.
145. c) Ragab, A. E.; Gruschow, S.; Rackham, E. J.; Goss, R. J. M. New pacidamycins biosynthetically: Probing N-and C-terminal substrate specificity. Org. Biomol. Chem. 2010, 8, 3128-3129.
146. d) Gruschow, S.; Rackham, E. J.; Goss, R. J. M. Diversity in natural product families is governed by more than enzyme promiscuity alone: Establishing control of the pacidamycin portfolio. Chem. Sci., 2011, 2, 2182-2186.
147. e) Walsh, C. T.; Zhang, W. Chemical logic and enzymatic machinery for biological assembly of peptidyl nucleoside antibiotics. ACS Chem. Biol., 2011, 6, 1000-1007.
148. f) Zhang, W.; Ntai, I.; Bolla, M. L.; Malcolmson, S. J.; Kahne, D.; Kelleher, N. L.; Walsh, C. T. Nine enzymes are required for assembly of the pacidamycin group of peptidyl nucleoside antibiotics. J. Am. Chem. Soc., 2011, 133, 5240-5243.
149. g) Rodis, M. T.; Mihalyi, A.; Ducho, C.; Eitei, K.; Gust, B.; Goss, R. J.; Bugg, T. D. Mechanism of action of the uridyl peptide antibiotics: An unexpected link to a protein-protein interaction site in translocase MraY. Chem. Commun., 2014, 50, 13023-13025.
150. Funabashi, M.; Baba. S.; Takatsu, T.; Kizuka, M.; Ohata, Y.; Tanaka, M.; Nonaka, K.; Spork, A. P.; Ducho, C.; Chen, W. L.; Van Lanen, S. G. Structure-based gene targeting discovery of sphaerimicin, a bacterial translocase I inhibitor. Angew. Chem. Int. Ed., 2013, 52, 11607-11611.
151. Murakami, R.; Fujita, Y.; Kizuka, M.; Kagawa, T.; Muramatsu, Y.; Miyakoshi, S.; Takatsu, T.; Inukai, M. A-94964, a novel inhibitor of bacterial translocase I, produced by Streptomyces sp. SANK 60404. I. Taxonomy, isolation and biological activity. J. Antibiot., 2008, 61, 537-534.